Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial

Jeffrey I Zwicker, Aaron P Kithcart, Justin Kaplan, Poulabi Banerjee, Keshini Vyas, Dan Chalothorn, José G Raya, Siyu Li, Laura E Fredenburgh, Mihaela Mocan, Rosen Razboynikov, Lori G Morton, David E Gutstein, Kathryn M Musgrave, Gregory Piazza, Mihaela Mocan, Rosen Razboynikov, Lucian Calmac, Jeffrey I Zwicker, Gregory Piazza, Gerald Soff, Hannah Lee, Ilana Kopolovic, Alejandro Lazo-Langner, Rashid Kazmi, Ariella Tvito, Amichay Meirovitz

Open source

DOI
10.1016/s2352-3026(26)00249-8
Published
2026-11
Container
The Lancet Haematology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00249-8,
  title = {Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial},
  author = {Jeffrey I Zwicker and Aaron P Kithcart and Justin Kaplan and Poulabi Banerjee and Keshini Vyas and Dan Chalothorn and José G Raya and Siyu Li and Laura E Fredenburgh and Mihaela Mocan and Rosen Razboynikov and Lori G Morton and David E Gutstein and Kathryn M Musgrave and Gregory Piazza and Mihaela Mocan and Rosen Razboynikov and Lucian Calmac and Jeffrey I Zwicker and Gregory Piazza and Gerald Soff and Hannah Lee and Ilana Kopolovic and Alejandro Lazo-Langner and Rashid Kazmi and Ariella Tvito and Amichay Meirovitz},
  year = {2026},
  journal = {The Lancet Haematology},
  doi = {10.1016/s2352-3026(26)00249-8},
  url = {https://doi.org/10.1016/s2352-3026(26)00249-8}
}

RIS

TY  - JOUR
TI  - Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial
AU  - Jeffrey I Zwicker
AU  - Aaron P Kithcart
AU  - Justin Kaplan
AU  - Poulabi Banerjee
AU  - Keshini Vyas
AU  - Dan Chalothorn
AU  - José G Raya
AU  - Siyu Li
AU  - Laura E Fredenburgh
AU  - Mihaela Mocan
AU  - Rosen Razboynikov
AU  - Lori G Morton
AU  - David E Gutstein
AU  - Kathryn M Musgrave
AU  - Gregory Piazza
AU  - Mihaela Mocan
AU  - Rosen Razboynikov
AU  - Lucian Calmac
AU  - Jeffrey I Zwicker
AU  - Gregory Piazza
AU  - Gerald Soff
AU  - Hannah Lee
AU  - Ilana Kopolovic
AU  - Alejandro Lazo-Langner
AU  - Rashid Kazmi
AU  - Ariella Tvito
AU  - Amichay Meirovitz
PY  - 2026
JO  - The Lancet Haematology
DO  - 10.1016/s2352-3026(26)00249-8
UR  - https://doi.org/10.1016/s2352-3026(26)00249-8
ER  - 

APA

Zwicker, J. I., Kithcart, A. P., Kaplan, J., Banerjee, P., Vyas, K., Chalothorn, D., Raya, J. G., Li, S., Fredenburgh, L. E., Mocan, M., Razboynikov, R., Morton, L. G., Gutstein, D. E., Musgrave, K. M., Piazza, G., Mocan, M., Razboynikov, R., Calmac, L., Zwicker, J. I., Piazza, G., Soff, G., Lee, H., Kopolovic, I., Lazo-Langner, A., Kazmi, R., Tvito, A., & Meirovitz, A. (2026). Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(26)00249-8

Source records